CytoMed Therapeutics vs XTL Biopharmaceuticals
GDTC and XTLB side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How GDTC and XTLB compare
CytoMed Therapeutics scores higher on the StockData Score (4 against 0 for XTL Biopharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | GDTC | XTLB |
|---|---|---|
| Size and price | ||
| Share price | $0.774 | $1.54 |
| Change, 1 year | −59.7% | −59.1% |
| Change, 5 years | – | −87.1% |
| Beta (5Y) | −0.40 | 1.21 |
| Employees | 5 | 3 |
| StockData Score | ||
| Total score | 4 (better) | 0 |
| Valuation score | 0 | 0 |
| Growth score | 1 (better) | 0 |
| Performance score | 1 (better) | 0 |
| Health score | 2 (better) | 0 |
| Dividend score | 0 | 0 |
| Growth | ||
| Revenue growth (TTM) | 367% | – |
| Profitability | ||
| Net margin | −1227% | – |
| FCF margin | −1336% | – |
| Return on equity | −51.3% | – |
| Financial health | ||
| Debt / equity | 0.06 | – |
| Interest coverage | – | −6.3× |
| Current ratio | 5.17 | – |
| Piotroski F-score | 1 | – |
| Ownership | ||
| Held by institutions | 0.10% | 0.00% |
| Held by insiders | 25.9% | 0.00% |
| Insider net buying, 12 months | $729K | – |
Go deeper
- GDTC stock overview
- GDTC income statement
- GDTC valuation and score
- XTLB stock overview
- XTLB income statement
- XTLB valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.